Parallel imaging of the cervical spine at 3T: optimized trade-off between speed and image quality.

BACKGROUND AND PURPOSE: Patients with cervical spine syndrome often experience pain during the MR examination. Our aim was to compare the quality of cervical spine MR images obtained by parallel imaging with those of nonaccelerated images, with the goal of shortening the examination time while preserving adequate image quality. MATERIALS AND METHODS: A phantom study and examinations of 10 volunteers and 26 patients were conducted on a clinical 3T scanner. Acquisitions included axial T2WI, sagittal T2WI, T1WI, and T2TIRM sequences. Nonaccelerated sequences and accelerated sequences with different numbers of averages and different accelerations, with a scanning time reduction of 67%, were performed. For quantitative analysis, the SNR was obtained from the phantom measurements, and the NU was calculated from the volunteer measurements. For qualitative analysis, 3 independent readers assessed the delineation of anatomic structures in volunteers and the visibility of degenerative disease in patients. RESULTS: In the phantom study, as expected, the SNR of the nonaccelerated images was higher than the SNR of the same sequence with parallel imaging. In vivo, the NU was higher when applying fewer averages or parallel imaging, compared with the nonaccelerated images. The analysis of the subjective parameters in the volunteers and patients showed that a scanning time of 48% of the original protocol could be obtained by combining the following sequences: sagittal T1WI with 1 average; sagittal T2WI with acceleration factor 3; sagittal T2TIRM with acceleration factor 2; and axial T2* GRE with acceleration factor 2. CONCLUSIONS: Parallel imaging of the cervical spine at 3T allows shortening of the examination time by 52%, preserving adequate image quality.

'In silico' oncology for clinical decision making in the context of nephroblastoma.

The present paper outlines the initial version of the ACGT (Advancing Clinico-Genomic Trials) -- an Integrated Project, partly funded by the EC (FP6-2005-IST-026996)I-Oncosimulator as an integrated software system simulating in vivo tumour response to therapeutic modalities within the clinical trials environment aiming to support clinical decision making in individual patients. Cancer treatment optimization is the main goal of the system. The document refers to the technology of the system and the clinical requirements and the types of medical data needed for exploitation in the case of nephroblastoma. The outcome of an initial step towards the clinical adaptation and validation of the system is presented and discussed. Use of anonymized real data before and after chemotherapeutic treatment for the case of the SIOP 2001/GPOH nephroblastoma clinical trial constitutes the basis of the clinical adaptation and validation process. By using real medical data concerning nephroblastoma for a single patient in conjunction with plausible values for the model parameters (based on available literature) a reasonable prediction of the actual tumour volume shrinkage has been made possible. Obviously as more and more sets of medical data are exploited the reliability of the model "tuning" is expected to increase. The successful performance of the initial combined ACGT Oncosimulator platform, although usable up to now only as a test of principle, has been a particularly encouraging step towards the clinical translation of the system, being the first of its kind worldwide.